US 12,410,232 B2
Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
Nicola Mason, Philadelphia, PA (US); Daniel J. Powell, Jr., Bala Cynwyd, PA (US); Mohammed Kazim Panjwani, Philadelphia, PA (US); Jenessa Smith, San Diego, CA (US); Laurence J.N. Cooper, Park City, UT (US); and Colleen M. O'Connor, Houston, TX (US)
Assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US); and Board of Regents, The University of Texas System, Austin, TX (US)
Filed by THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US); and Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Aug. 31, 2021, as Appl. No. 17/462,925.
Application 17/462,925 is a continuation of application No. 15/743,033, granted, now 11,116,795, previously published as PCT/US2016/041557, filed on Jul. 8, 2016.
Claims priority of provisional application 62/191,048, filed on Jul. 10, 2015.
Prior Publication US 2022/0168351 A1, Jun. 2, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 40/31 (2025.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01)
CPC C07K 14/70517 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4221 (2025.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/2887 (2013.01); C12N 5/0638 (2013.01); A61K 2039/552 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01)] 8 Claims
 
1. A method of treating a CD20+ cancer in a canine, the method comprising administering to the canine a modified cell that expresses a chimeric antigen receptor comprising a canine CD20 antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the canine CD20 antigen binding domain comprises an anti-CD20 single-chain variable fragment (scFv) comprising SEQ ID NO: 2.